Combined Effects of Obesity, Acid Reflux and Smoking on the Risk of Adenocarcinomas of the Oesophagus
Overview
Affiliations
Objective: To measure the relative risks of adenocarcinomas of the oesophagus and gastro-oesophageal junction associated with measures of obesity, and their interactions with age, sex, gastro-oesophageal reflux symptoms and smoking.
Design And Setting: Population-based case-control study in Australia.
Patients: Patients with adenocarcinomas of the oesophagus (n = 367) or gastro-oesophageal junction (n = 426) were compared with control participants (n = 1580) sampled from a population register.
Main Outcome Measure: Relative risk of adenocarcinoma of the oesophagus or gastro-oesophageal junction.
Results: Risks of oesophageal adenocarcinoma increased monotonically with body mass index (BMI) (p(trend) <0.001). Highest risks were seen for BMI >or=40 kg/m2 (odds ratio (OR) = 6.1, 95% CI 2.7 to 13.6) compared with "healthy" BMI (18.5-24.9 kg/m2). Adjustment for gastro-oesophageal reflux and other factors modestly attenuated risks. Risks associated with obesity were substantially higher among men (OR = 2.6, 95% CI 1.8 to 3.9) than women (OR = 1.4, 95% CI 0.5 to 3.5), and among those aged <50 years (OR = 7.5, 95% CI 1.7 to 33.0) than those aged >or=50 years (OR = 2.2, 95% CI 1.5 to 3.1). Obese people with frequent symptoms of gastro-oesophageal reflux had significantly higher risks (OR = 16.5, 95% CI 8.9 to 30.6) than people with obesity but no reflux (OR = 2.2, 95% CI 1.1 to 4.3) or reflux but no obesity (OR = 5.6, 95% 2.8 to 11.3), consistent with a synergistic interaction between these factors. Similar associations, but of smaller magnitude, were seen for gastro-oesophageal junction adenocarcinomas.
Conclusions: Obesity increases the risk of oesophageal adenocarcinoma independently of other factors, particularly among men. From a clinical perspective, these data suggest that patients with obesity and frequent symptoms of gastro-oesophageal reflux are at especially increased risk of adenocarcinoma.
Bacoeur-Ouzillou O, Guerrier L, Touron J, Pinel A, Pereira B, Meunier N BMJ Open. 2024; 14(10):e086686.
PMID: 39448207 PMC: 11499755. DOI: 10.1136/bmjopen-2024-086686.
Bibliometric and visual analysis of esophagogastric junction cancer research from 2002 to 2021.
Wang Z, Li X, Hu J, Guo X, Gao B, Zhu B Medicine (Baltimore). 2024; 103(20):e38100.
PMID: 38758908 PMC: 11098202. DOI: 10.1097/MD.0000000000038100.
Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.
Li S, Hoefnagel S, Krishnadath K Cancers (Basel). 2023; 15(22).
PMID: 38001670 PMC: 10670638. DOI: 10.3390/cancers15225410.
Agarwal S, Bell M, Dhaliwal L, Codipilly D, Dierkhising R, Lansing R Dig Dis Sci. 2023; 69(1):246-253.
PMID: 37914889 PMC: 10926253. DOI: 10.1007/s10620-023-08126-6.
Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer.
Wang X, Tian R, Zong X, Jeon M, Luo J, Colditz G Cancer Epidemiol Biomarkers Prev. 2023; 32(8):1079-1086.
PMID: 37195052 PMC: 10525008. DOI: 10.1158/1055-9965.EPI-23-0101.